Abstract

BackgroundABO blood groups have previously been associated with cardiovascular disease (CVD) in the general population. This study aimed to investigate the potential relationship between ABO blood groups and CVD in individuals with type 1 diabetes according to diabetic nephropathy (DN) status.MethodsAdults with type 1 diabetes (4531 individuals) from the FinnDiane Study were evaluated. DN was determined by two out of three measurements of urinary albumin excretion rate. Albuminuria was defined as an excretion rate above 20 µg/min. CVD events were identified by linking the data with the Finnish Care Register for Health Care and the Finnish Cause of Death Register. Follow-up ranged from the baseline visit until a CVD event, death or the end of 2017. The impact of ABO blood groups on CVD risk was estimated by multivariable Cox-regression analyses adjusted for traditional risk factors.ResultsAt baseline, the median age was 38.5 (IQR 29.2–47.9) years, 47.5% were female and median duration of diabetes was 20.9 (11.4–30.7) years. There were 893 incident ischemic heart disease (IHD) events, 301 ischemic strokes (IS), and 415 peripheral artery disease (PAD) events during a median follow up of 16.5 (IQR 12.8–18.6) years. The A blood group showed the highest risk of IHD versus the O blood group, when microalbuminuria was present. Comparing the population with microalbuminuria with those with normoalbuminuria, only the A blood group elevated the risk of IHD. This increased risk was neither explained by the FUT2 secretor phenotype nor by the A-genotype distribution. The risk of IS or PAD was no different among the ABO blood groups regardless of diabetic nephropathy stage.ConclusionThe A blood group is a risk factor for IHD in individuals with type 1 diabetes and microalbuminuria.

Highlights

  • ABO blood groups have previously been associated with cardiovascular disease (CVD) in the general population

  • This study aimed to explore this unanswered question taking different diabetic nephropathy (DN) stages into account. Research design This is an observational prospective study to evaluate the relationship between ABO blood groups and CVD in type 1 diabetes according to DN stage as part of the ongoing Finnish Diabetic Nephropathy (FinnDiane) Study, which is a nationwide, prospective, multicenter study aiming to identify risk factors for type 1 diabetes complications

  • There were 893 incident ischemic heart disease (IHD) events, 301 ischemic strokes (IS) and 415 peripheral artery disease (PAD) events during 62,326 person-years for IHD, 68,137 for IS and 67,118 for PAD during a median follow up of 16.5 (IQR 12.8–18.6) years. Baseline characteristics such as the prevalence of IHD, FUT2 secretor phenotype, number of antibiotic purchases per person per year, serum hs-C-reactive peptide (CRP) level, DN stages and other well-known CVD risk factors were no different between the ABO blood groups (Table 1)

Read more

Summary

Introduction

ABO blood groups have previously been associated with cardiovascular disease (CVD) in the general population. ABO antigens are not expressed only on the surface of red blood cells but Parente et al Cardiovasc Diabetol (2020) 19:68 on epithelial and endothelial cells, T-cells, B-cells and platelets [8]. These antigens might be found in the circulation and body secretions, if the individual has the FUT2 gene secretor phenotype [8]. Different levels of the von Willebrand factor (vWF) [10] and HDL-cholesterol concentrations [11] have been suggested to explain the relationship between ABO blood groups and CVD risk

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.